What are expected or possible consequences of over-estimation
of recruitment potential? - CORRECT ANSWER - The trial will
overrun its projected timeline
- The recruitment period will be prolonged and more sites may be
needed
- The study will not have sufficient data within the required
timeframe and will be stopped because of lack of budget
What should be the first consideration when conducting a clinical
trial? - CORRECT ANSWER Subject welfare
When is the investigator allowed to deviate from the protocol? -
CORRECT ANSWER When there is an immediate hazard to a
patient.
If the investigator wanted to deviate from the protocol for an
immediate hazard to a patient, according to ICH E6 guidelines
who world they need to report the deviation and rationale to, if
appropriate? - CORRECT ANSWER - The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into
your trial? - CORRECT ANSWER - Subject meets all inclusion
criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP.
The study drug must be stored below 25C/77F. On a summer
Monday morning you discover that the temperature recording
machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the
current temperature; it's 24C/75F. What should you do? -
CORRECT ANSWER - Contact the Sponsor, explain what
happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received
IRB approval for the amendment and wants to implement the
increase in PO dose for your trial subjects as identified in the
amendment trial subjects. As delegated consenting duties you
must re-consent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who
are still taking the IP and not from the subjects woh already
completed their drug intake period. Is this allowed according the
E6 Guideline for GCP? - CORRECT ANSWER No, these
subjects are still enrolled in the trial and therefore need to be
updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in
the trial. What should your course of action be? - CORRECT
ANSWER You ask if the patient wishes to share the reason why
she wants to leave the trial. If not, you exclude the subject from
the trial immediately.
A patient cannot recall the name of the heart condition medication
he took a few years ago. This is important information for deciding
whether the patient may be enrolled in a clinical trial (IC/EC).
What's your best course of action? - CORRECT ANSWER You
attempt to retrieve the patients medical history by contacting
previous caregivers and you wait for additional information before
enrollment.
Who has ultimate trial responsibility for each subject? -
CORRECT ANSWER The principle investigator.
Category | exam bundles |
Comments | 0 |
Rating | |
Sales | 0 |